AngioDynamics(ANGO) - 2022 Q4 - Earnings Call Presentation

Financial Performance - AngioDynamics' overall revenue increased by 9.6% year-over-year, reaching $76.971 million in Q1 FY2022 compared to $70.216 million in Q1 FY2021[5, 8, 13] - Gross margin improved by 120 basis points, reaching 52.1% in Q1 FY2022 from 50.9% in Q1 FY2021[8, 13] - Net loss was ($6.972) million in Q1 FY2022, compared to ($4.268) million in Q1 FY2021[8, 13] - Adjusted EPS was ($0.02) in Q1 FY2022, compared to $0.02 in Q1 FY2021[8, 13] - Adjusted EBITDA was $3.570 million in Q1 FY2022, compared to $4.466 million in Q1 FY2021[8, 13] Product and Segment Performance - Auryon sales reached $5.9 million[5] - AngioVac experienced a 12% year-over-year growth[5, 10] - NanoKnife disposables showed worldwide growth of 34% year-over-year and US growth of 63% year-over-year[5, 9, 10] - NanoKnife capital experienced a 280% growth[9, 10] Strategic Initiatives - The company commenced a Limited Market Release of the AlphaVac Mechanical Thrombectomy device in September[5] - Acquired a support catheter for the Auryon platform, funded by a $5.0 million draw on the revolving credit facility[5]